The dual failure in progression-free survival and overall survival likely puts Krazati’s approval in colorectal cancer at risk.
While Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company…
Exelixis' zanzalintinib misses OS endpoint in mCRC subgroup without liver mets; FDA decision on all-comers approval due Dec 3.
Bristol Myers Squibb’s next-gen multiple myeloma drug mezigdomide cut the risk of disease progression or death for certain…
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology…
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares…
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over…
